ConcertAI CEO Eron Kelly on Big Tech's role in biotech

This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development.

ConcertAI sits at the intersection of life sciences and large-scale data, working with biopharma companies, research networks, and technology partners to turn real-world clinical and genomic information into insights that can guide drug development decisions.

Mr Kelly stepped into the CEO role after a career in big tech, including senior leadership positions at Microsoft and AWS. He now brings that experience to a business that has attracted significant attention during a wave of AI-fuelled investor optimism.

The company has also been busy on the partnering front, with a major strategic agreement announced with Bayer (BAYN: DE) and a newer collaboration with Foundation Medicine, both focused on leveraging data and AI to speed cancer drug development.

In this episode, we’ll talk about Mr Kelly’s first months in the job, what he’s hearing from partners in the industry, and where AI continues to move the needle in biotech.